High-Quality Thymosin Alpha 1 62304-98-7 Pricelist, Service
Product Description
The drug's primary therapeutic areas focus on infectious diseases, cancer, and immunodeficiency-related diseases. Specifically, these include:
Infectious Diseases
Used as adjunctive therapy for chronic hepatitis B (HBV) and chronic hepatitis C (HCV) to enhance vaccine response; also used for immune support in severe infections (such as sepsis) and respiratory infections.
Oncology
As an adjunct to radiotherapy and chemotherapy, it is used to improve immunosuppressive states (such as advanced liver cancer, lung cancer, etc.) and enhance anti-tumor immunity.
Immunodeficiency Diseases
Used as adjunctive therapy for primary immunodeficiency diseases and acquired immunodeficiency (such as immune reconstitution in HIV/AIDS patients).
Other Applications
In recent years, research has expanded to autoimmune diseases, immune regulation after severe viral infections such as COVID-19, and its application as a vaccine adjuvant.
The future development prospects of Thymosin Alpha 1 are promising, mainly focusing on the following areas:
Expanding Indications
There is increasing research in autoimmune diseases, age-related immune decline, and novel viral infections (such as long-term COVID-19 immune recovery).
Combination Therapy
Combining with immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors, chemotherapy, or targeted drugs to enhance anti-tumor efficacy has become a research hotspot in tumor immunotherapy.
Novel Formulations
The development of long-acting sustained-release formulations and oral formulations (such as enteric-coated capsules) is expected to improve patient compliance and expand the scope of application.
Deeper Mechanisms
With the advancement of immunological research, its more refined molecular mechanisms (such as the regulation of specific T cell subsets and dendritic cells) are being further elucidated, providing a basis for precision treatment.
Global Market Growth
Particularly in the Asia-Pacific region, the clinical application and market for immunotherapy are expected to continue to grow due to the rising incidence of infectious diseases and cancer, as well as the increasing demand for immunotherapy.
Thymosin Alpha 1 is a 28-amino acid polypeptide isolated from thymic tissue. It regulates the immune system by enhancing T cell differentiation, maturation, and function, while promoting cytokine production to modulate both innate and adaptive immune responses.
It is primarily used to treat infectious diseases (like chronic hepatitis B and C, sepsis), as an adjunct in oncology treatments (liver and lung cancer), and for immunodeficiency-related disorders such as HIV/AIDS.
It acts as an adjunct to chemotherapy and radiotherapy to counteract immunosuppressive states, boosting anti-tumor immunity and helping patients tolerate aggressive treatments better.
Key developments focus on new indications (such as long-term COVID-19 immune recovery), combination therapies with PD-1/PD-L1 inhibitors, and user-friendly formulations like sustained-release or oral enteric-coated capsules.
Yes, Thymosin Alpha 1 exhibits a high safety profile, making it a widely trusted and commonly prescribed immune enhancer in clinical practice worldwide.
